GlassScriptPhysician profile
Indira Vanguru
NPI 1215248216
$5,487.50
in general payments reported to CMS, 2019-2025
29 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $219 · 2021: $389 · 2022: $1,181 · 2023: $997 · 2024: $619 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,131.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $860.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $780.53 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.43 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $340.12 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $237.16 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $236.46 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $197.99 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Abbvie INC. | $190.15 | 2022-2024 | Linzess, Ubrelvy, Viberzi |
| Abbott Laboratories | $181.58 | 2021-2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $156.10 | 2019-2025 | |
| Dexcom, INC. | $113.93 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $95.10 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $92.49 | 2023-2025 | Heplisav-B |
| Genentech USA, INC. | $73.88 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $44.31 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $42.19 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $41.63 | 2022-2025 | |
| Astellas Pharma US INC | $34.08 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $27.05 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $26.76 | 2019 | |
| Axsome Therapeutics, INC. | $25.44 | 2025 | Symbravo |
| Ibsa Pharma INC. | $23.48 | 2025 | Flector, Licart, Tirosint |
| Teva Pharmaceuticals USA, INC. | $19.66 | 2023 | Ajovy |
| Bioventus LLC | $16.59 | 2019 | |
| Hologic Sales and Service, LLC | $16.02 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.03 | 2021 | |
| Allergan, INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Vanguru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.